SUMOylation of Myc-family proteins

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Sabò, Arianna ^a,b   Doni, Mirko ^b   Amati, Bruno ^a,b  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; MYC PROTEIN; PROTEASOME; SUMO PROTEIN; LYSINE; MUTANT PROTEIN;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL STRESS; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; NEUROBLASTOMA CELL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STABILITY; SUMOYLATION; TRANSCRIPTION REGULATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; HEAT SHOCK RESPONSE; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE; PHYSIOLOGICAL STRESS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; HEAT-SHOCK RESPONSE; HUMANS; LYSINE; MICE; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; STRESS, PHYSIOLOGICAL; SUMOYLATION;

EID: 84897393215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091072     Document Type: Article

References (65)

1. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016. doi:10.1038/sj.onc.1202746. (Pubitemid 29276540)
2. Küppers R, Dalla-Favera R (2001) Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20: 5580-5594. doi:10.1038/sj.onc. 1204640. (Pubitemid 32928099)
3. Sharma VM, Draheim KM, Kelliher MA (2007) The Notch1/c-Myc pathway in T cell leukemia. Cell Cycle 6: 927-930. (Pubitemid 46658747)
4. Efstratiadis A, Szabolcs M, Klinakis A (2007) Notch, Myc and breast cancer. Cell Cycle 6: 418-429. (Pubitemid 46393444)
5. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, et al. (2007) Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676-679. doi:10.1038/nature05674. (Pubitemid 46606884)
6. Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G, et al. (1996) Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 14: 25-34. (Pubitemid 26019993)
7. Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, et al. (1997) N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol 15: 1171-1182. (Pubitemid 27106305)
8. Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M (1998) Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J Clin Oncol 16: 3286-3294. (Pubitemid 28481623)
9. Cohn SL, Pearson ADJ, London WB, Monclair T, Ambros PF, et al. (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289-297. doi:10.1200/JCO.2008.16.6785.
10. Sur I, Tuupanen S, Whitington T, Aaltonen LA, Taipale J (2013) Lessons from Functional Analysis of Genome-Wide Association Studies. Cancer Res 73: 4180-4184. doi:10.1158/0008-5472.CAN-13-0789.
11. Eilers M, Eisenman RN (2008) Myc's broad reach. Genes Dev 22: 2755-2766. doi:10.1101/gad.1712408.
12. Dani C, Blanchard JM, Piechaczyk M, Sabouty El S, Marty L, et al. (1984) Extreme instability of myc mRNA in normal and transformed human cells. Proc Natl Acad Sci USA 81: 7046-7050. (Pubitemid 15216694)
13. Ramsay G, Evan GI, Bishop JM (1984) The protein encoded by the human proto-oncogene c-myc. Proc Natl Acad Sci USA 81: 7742-7746. (Pubitemid 15169137)
14. Hann SR, Eisenman RN (1984) Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 4: 2486-2497. (Pubitemid 15212264)
15. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, et al. (2000) Multiple Rasdependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514.
16. Rabbitts TH, Hamlyn PH, Baer R (1983) Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma. Nature 306: 760-765. (Pubitemid 14206039)
17. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, et al. (1993) Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 5: 56-61. doi:10.1038/ng0993-56. (Pubitemid 23261519)
18. Clark HM, Yano T, Otsuki T, Jaffe ES, Shibata D, et al. (1994) Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas. Cancer Res 54: 3383-3386. (Pubitemid 24225954)
19. Bhatia K, Spangler G, Gaidano G, Hamdy N, Dalla-Favera R, et al. (1994) Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. Blood 84: 883-888. (Pubitemid 24223886)
20. Bahram F, Lehr von der N, Cetinkaya C, Larsson LG (2000) c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 95: 2104-2110.
21. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, et al. (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature: 1-5. doi:10.1038/nature11378.
22. Love C, Sun Z, Jima D, Li G, Zhang J, et al. (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet: 1-7. doi:10.1038/ng.2468.
23. Giulino-Roth L, Wang K, MacDonald TY, Mathew S, Tam Y, et al. (2012) Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes. Blood 120: 5181-5184. doi:10.1182/blood-2012-06-437624.
24. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, et al. (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23: 2116-2125. doi:10.1038/sj.emboj.7600217. (Pubitemid 38737738)
25. Welcker M, Orian A, Jin J, Grim JE, Grim JA, et al. (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101: 9085-9090. doi:10.1073/pnas.0402770101. (Pubitemid 38781615)
26. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, et al. (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nat Cell Biol 436: 807-811. doi:10.1038/nature03845. (Pubitemid 41160633)
27. Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, et al. (2009) Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15: 67-78. doi:10.1016/j.ccr.2008.12.005.
28. Vervoorts J, Luscher-Firzlaff J, Luscher B (2006) The Ins and Outs of MYC Regulation by Posttranslational Mechanisms. Journal of Biological Chemistry 281: 34725-34729. doi:10.1074/jbc.R600017200. (Pubitemid 46036511)
29. Matunis MJ, Coutavas E, Blobel G (1996) A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J Cell Biol 135: 1457-1470. (Pubitemid 26427644)
30. Chen A, Mannen H, Li SS (1998) Characterization of mouse ubiquitin-like SMT3A and SMT3B cDNAs and gene/pseudogenes. Biochem Mol Biol Int 46: 1161-1174. (Pubitemid 29027173)
31. Kamitani T, Kito K, Nguyen HP, Fukuda-Kamitani T, Yeh ET (1998) Characterization of a second member of the sentrin family of ubiquitin-like proteins. J Biol Chem 273: 11349-11353. (Pubitemid 28204990)
32. Saitoh H (2000) Functional Heterogeneity of Small Ubiquitin-related Protein Modifiers SUMO-1 versus SUMO-2/3. Journal of Biological Chemistry 275: 6252-6258. doi:10.1074/jbc.275.9.6252.
33. Tatham MH (2001) Polymeric Chains of SUMO-2 and SUMO-3 Are Conjugated to Protein Substrates by SAE1/SAE2 and Ubc9. Journal of Biological Chemistry 276: 35368-35374. doi:10.1074/jbc.M104214200.
34. Kerscher O (2007) SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep 8: 550-555. doi:10.1038/sj.embor. 7400980.
35. Geiss-Friedlander R, Melchior F (2007) Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8: 947-956. doi:10.1038/nrm2293. (Pubitemid 350176509)
36. Wang Y, Dasso M (2009) SUMOylation and deSUMOylation at a glance. Journal of Cell Science 122: 4249-4252. doi:10.1242/jcs.050542.
37. Wilkinson KA, Henley JM (2010) Mechanisms, regulation and consequences of protein SUMOylation. Biochem J 428: 133-145. doi:10.1042/BJ20100158.
38. Bettermann K, Benesch M, Weis S, Haybaeck J (2011) SUMOylation in carcinogenesis. Cancer Lett. doi:10.1016/j.canlet.2011.10.036.
39. Jentsch S, Psakhye I (2012) Control of Nuclear Activities by Substrate-Selective and Protein-Group SUMOylation. Annu Rev Genet 47: 130909162859001. doi:10.1146/annurev-genet-111212-133453.
40. Amente S, Lavadera ML, Palo GD, Majello B (2012) SUMO-activating SAE1 transcription is positively regulated by Myc. Am J Cancer Res 2: 330-334.
41. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, et al. (2011) A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc- Driven Tumorigenesis. Science. doi:10.1126/science.1212728.
42. Neyret-Kahn H, Benhamed M, Ye T, Le Gras S, Cossec JC, et al. (2013) Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation. Genome Research. doi:10.1101/gr.154872.113.
43. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, et al. (2010) Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 12: 54-9-suppp1-14. doi:10.1038/ncb2004.
44. Miteva M, Keusekotten K, Hofmann K, Praefcke GJK, Dohmen RJ (2010) Sumoylation as a signal for polyubiquitylation and proteasomal degradation. Subcell Biochem 54: 195-214. doi:10.1007/978-1-4419-6676-6-16.
45. Cowling VH, Chandriani S, Whitfield ML, Cole MD (2006) A conserved Myc protein domain, MBIV, regulates DNA binding, apoptosis, transformation, and G2 arrest. Mol Cell Biol 26: 4226-4239. doi:10.1128/MCB.01959-05. (Pubitemid 43788022)
46. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H (1990) Sequence-specific DNA binding by the c-Myc protein. Science 250: 1149-1151. (Pubitemid 120031826)
47. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, et al. (1992) Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359: 423-426. doi:10.1038/359423a0.
48. Blackwell TK, Huang J, Ma A, Kretzner L, Alt FW, et al. (1993) Binding of myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol 13: 5216-5224. (Pubitemid 23260626)
49. Ulrich HD (2005) Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol 15: 525-532. doi:10.1016/j.tcb.2005.08.002.
50. Praefcke GJK, Hofmann K, Dohmen RJ (2012) SUMO playing tag with ubiquitin. Trends Biochem Sci 37: 23-31. doi:10.1016/j.tibs.2011.09.002.
51. Patel JH, Du Y, Ard PG, Phillips C, Carella B, et al. (2004) The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 24: 10826-10834. doi:10.1128/MCB.24.24.10826-10834.2004. (Pubitemid 39603138)
52. Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, et al. (2005) The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123: 409-421. doi:10.1016/j.cell. 2005.08.016. (Pubitemid 41546672)
53. Zhang K, Faiola F, Martinez E (2005) Six lysine residues on c-Myc are direct substrates for acetylation by p300. Biochemical and Biophysical Research Communications 336: 274-280. doi:10.1016/j.bbrc.2005.08.075. (Pubitemid 41253431)
54. Faiola F, Liu X, Lo S, Pan S, Zhang K, et al. (2005) Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol Cell Biol 25: 10220-10234. doi:10.1128/MCB.25.23.10220-10234.2005. (Pubitemid 41681950)
55. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI (1995) A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690.
56. Johnson ES (2004) P ROTEINM ODIFICATION BYSUMO. Annu Rev Biochem 73: 355-382. doi:10.1146/annurev.biochem.73.011303.074118.
57. Galderisi U, Di Bernardo G, Cipollaro M, Peluso G, Cascino A, et al. (1999) Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product. J Cell Biochem 73: 97-105. (Pubitemid 29115483)
58. Kang J-H, Rychahou PG, Ishola TA, Qiao J, Evers BM, et al. (2006) MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochemical and Biophysical Research Communications 351: 192-197. doi:10.1016/j.bbrc.2006.10.020. (Pubitemid 44635425)
59. Yu U-Y, Cha J-E, Ju S-Y, Cho K-A, Yoo E-S, et al. (2008) Effect on cell cycle progression by N-Myc knockdown in SK-N-BE(2) neuroblastoma cell line and cytotoxicity with STI-571 compound. Cancer Res Treat 40: 27-32. doi:10.4143/crt.2008.40.1.27.
60. Jiang R, Xue S, Jin Z (2011) Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Biochemical and Biophysical Research Communications 410: 364-370. doi:10.1016/j.bbrc.2011.06.020.
61. Henriksen JR, Haug BH, Buechner J, Tømte E, Løkke C, et al. (2011) Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma. BMC Developmental Biology 11: 1. doi:10.1186/1471-213X-11-1.
62. Golebiowski F, Matic I, Tatham MH, Cole C, Yin Y, et al. (2009) System-wide changes to SUMO modifications in response to heat shock. Science Signaling 2: ra24. doi:10.1126/scisignal.2000282.
63. Tatham MH, Matic I, Mann M, Hay RT (2011) Comparative proteomic analysis identifies a role for SUMO in protein quality control. Science Signaling 4: rs4. doi:10.1126/scisignal.2001484.
64. Castorálová M, Březinová D, Svéda M, Lipov J, Ruml T, et al. (2012) SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis. Biochim Biophys Acta. doi:10.1016/j.bbamcr.2012.01.010.
65. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, et al. (2007) The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 9: 765-774. doi:10.1038/ncb1601. (Pubitemid 47019463)